Patent application number | Description | Published |
20080274468 | NOVEL MEANS FOR THE DIAGNOSIS AND THERAPY OF CTCL - The invention relates to a novel molecule, termed SC5 by the inventors, to a novel allelic form of p140, and to the biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL. | 11-06-2008 |
20090317401 | Angiogenic and immunoglobic applications of anti cd160 specific compounds obtainable from mab cl 1-r2 - The present invention relates to biological and medical application of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) an of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD 160 compounds in the fields of EC angiogenesis, and NK and T cytokine production | 12-24-2009 |
20100008932 | USE OF SOLUBLE CD160 TO SUPPRESS IMMUNITY - Pharmaceutical composition including a soluble form of CD160 for treating an inflammatory condition involving an undesired immune response, such as tissue graft or organ rejection, and autoimmune diseases; in vitro method for screening an individual for the presence of an inflammatory condition such as infectious and autoimmune diseases, tissue graft and organ rejection, or the presence of a tumor or activated endothelial cells, or for monitoring therapy of an inflammatory condition such as an autoimmune disorder or a tissue or organ rejection, or a tumor during chemotherapy including treatment with an anti-angiogenic substance or antibody. | 01-14-2010 |
20100234294 | IDENTIFICATION OF NEW ISOFORMS OF THE MHC-CLASS I SPECIFIC RECEPTOR CD160 AND USES THEREOF - The present invention concerns an isolated polypeptide comprising a sequence selected in the group comprising SEQ ID NO.7, its orthologs, and derivatives thereof; a polynucleotide comprising a nucleic acid sequence encoding for said polypeptide; a vector comprising said polynucleotide; a host cell genetically engineered with said polynucleotide or with said vector; a pharmaceutical composition comprising said polypeptide, a polynucleotide coding for said polypeptide or a vector comprising said polynucleotide, and optionally a pharmaceutically acceptable carrier; a method for screening for antagonists and/or agonists of said polypeptide; and uses of said polypeptide, a polynucleotide coding for said polypeptide or a vector comprising said polynucleotide, for the manufacture of a medicament. | 09-16-2010 |
20110151472 | NOVEL MEANS FOR THE DIAGNOSIS AND THERAPY OF CTCL - The invention relates to a novel molecule, termed SC5 by the inventors, to a novel allelic form of p140, and to the biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL. | 06-23-2011 |
20110311544 | Anti-cd71 Monoclonal Antibodies and Uses Thereof for Treating Malignant Tumor Cells - The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumour cells, especially metastatic cutaneous and uveal melanoma cells. | 12-22-2011 |
20120003224 | ANGIOGENIC AND IMMUNOLOGIC APPLICATIONS OF ANTI-CD160 SPECIFIC COMPOUNDS OBTAINABLE FROM mAb CL1-R2 - The present invention relates to biological and medical applications of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) and of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD160 compounds in the fields of EC angiogenesis, and NK and T cytokine production. | 01-05-2012 |
20120027758 | USE OF ANTI-CD100 ANTIBODIES - The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized or human form thereof, or a fragment thereof, for the therapy or diagnosis of a central nervous system disorder, more particularly a myelin disorder or a disease that affects oligodendrocytes, such as multiple sclerosis or HTLV-1 associated myelopathy or peripheral myelinating cells. | 02-02-2012 |
20120329063 | NOVEL MEANS FOR THE DIAGNOSIS AND THERAPY OF CTCL - The invention relates to a novel molecule, termed SC5 by the inventors, to a novel allelic form of p140, and to the biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL. | 12-27-2012 |
20130122006 | ANTI-CD160 SPECIFIC ANTIBODIES FOR THE TREATMENT OF EYE DISORDERS BASED ON NEOANGIOGENESIS - The present invention relates to the use of at least one anti-CD 160 antibody, preferably a compound selected from CL1-R2 monoclonal antibody (which may be obtained by the hybridoma CNCM I-3204), its conservative fragments and its conservative derivatives, for preparing a drug designed to treat neovascular eye diseases. | 05-16-2013 |
20130273062 | ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF - Disclosed are CD39 antagonists that can inhibit the immunosuppressive effect of a CD39-expressing cancerous cell, and methods of using the CD39 antagonists. | 10-17-2013 |
20140120110 | ANGIOGENIC AND IMMUNOLOGIC APPLICATIONS OF ANTI-CD160 SPECIFIC COMPOUNDS OBTAINABLE FROM mAb CL1-R2 - The present invention relates to biological and medical applications of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) and of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD160 compounds in the fields of EC angiogenesis, and NK and T cytokine production. | 05-01-2014 |
Patent application number | Description | Published |
20110013980 | CONNECTING ASSEMBLY FOR TOOLS AND HANDLES - A connecting assembly is provided that includes a tool receiving portion, a handle receiving portion, a tightening member, a first open region, and a second open region. The handle receiving portion has a first engaging portion, a clamping portion with a first cam, and a longitudinal axis. The tightening member has a second cam and a second engaging portion. The second engaging portion is engagable with the first engaging portion so that the tightening member moves to cause the first and second cams to interact with one another biasing the clamping portion in a desired direction. The first open region is defined at the first engaging portion, while the second open region is defined at the clamping portion so that the open regions are in fluid communication with one another. | 01-20-2011 |
20120174332 | SURFACE CLEANING TOOLS HAVING END CAPS - An end cap having a longitudinal axis is provided. The end cap includes a stationary portion, a movable portion, and a clamping member. The movable portion has a cam surface and the clamping member has a free end. The movable and stationary portions are interconnected so that the movable portion moves between a locked position and an unlocked position. The cam surface influences the clamping member when the movable portion is in the locked position such that the cam surface resiliently flexes the clamping member to move the free end at least perpendicular to the longitudinal axis. | 07-12-2012 |
20140215795 | SURFACE CLEANING TOOLS HAVING END CAPS - An end cap having a longitudinal axis is provided. The end cap includes a stationary portion, a movable portion, and a clamping member. The movable portion has a cam surface and the clamping member has a free end. The movable and stationary portions are interconnected so that the movable portion moves between a locked position and an unlocked position. The cam surface influences the clamping member when the movable portion is in the locked position such that the cam surface resiliently flexes the clamping member to move the free end at least perpendicular to the longitudinal axis. | 08-07-2014 |